|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Rainbow BioSciences, LLC: Alzheimer's Epidemic Draws $100 Million in Research
10/24/2012 9:00:53 AM
NOKOMIS, Fla.--(BUSINESS WIRE)--As Rainbow Coral Corp.’s (OTCBB:RBCC) biotech subsidiary, Rainbow BioSciences, nears a deal with Amarantus BioSciences (OTCBB: AMBS), the Alzheimer’s epidemic is already drawing $100 million worth of disease research from big drug companies. A $100 million drug trial will begin next year in the isolated villages of Antioquia, Columbia, where a genetic mutation in the community’s blood line has led to a higher concentration of Alzheimer’s sufferers than anywhere else in the world. About 5,000 residents of the area now form the biggest and best pool of potential Alzheimer’s patients anywhere—a solid trial group for drug companies working on a cure. “This massive research expenditure in Columbia just goes to show how desperate the world is for a cure to this disease,” said RBCC CEO Patrick Brown. “There is a huge a market developing around the globe for effective new Alzheimer’s treatments, and we’re working very hard to capitalize on that demand.”
|
|
|
|
|
|
|
|
|
|
|